Financial Oversight and Management Board for Puerto Rico

DGAP-News: BRAIN Biotech AG publishes Annual Report for FY 2020/21

Retrieved on: 
Monday, January 17, 2022 - 7:04am

BRAIN Biotech AG today published its Annual Report for the fiscal year 2020/21.

Key Points: 
  • BRAIN Biotech AG today published its Annual Report for the fiscal year 2020/21.
  • In 2020 the new executive management team at BRAIN Biotech AG had initiated a crucial transformation process at Germany's industrial biotech pioneer.
  • BRAIN Biotech AG ("BRAIN") is a leading European industrial biotechnology specialist with a focus on nutrition, health and the environment.
  • Numerous factors exist that could influence the future performance by, and future developments at, BRAIN Biotech AG and the BRAIN Group.

DGAP-News: Frankfurt/Main Higher Regional Court appoints Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis to the Supervisory Board of Aareal Bank

Retrieved on: 
Friday, January 14, 2022 - 3:06pm

Frankfurt/Main Higher Regional Court appoints Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis to the Supervisory Board of Aareal Bank

Key Points: 
  • Frankfurt/Main Higher Regional Court appoints Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis to the Supervisory Board of Aareal Bank
    The issuer is solely responsible for the content of this announcement.
  • Frankfurt/Main Higher Regional Court appoints Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis to the Supervisory Board of Aareal Bank
    - Prof. Dr Hermann Wagner: "We welcome the decision taken by the Higher Regional Court.
  • Wiesbaden, 14 January 2022 - With a binding decision, the Frankfurt/Main Higher Regional Court approved the application submitted by Aareal Bank to appoint Messrs Holger Giese, Friedrich Munsberg and Dr Ulrich Theileis as members of Aareal Bank's Supervisory Board, with immediate effect.
  • Prof. Dr Hermann Wagner, the Chairman of the Supervisory Board of Aareal Bank AG, commented: "We welcome the decision taken by the Higher Regional Court.

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

Retrieved on: 
Friday, January 14, 2022 - 7:00am

These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.

Key Points: 
  • These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.
  • Marcin Szumowski, Co-founder & CEO, commented, "We arepleased towelcome Nancy, Paul and Rafal as new members to the Supervisory Board.
  • Together, they bring a deep understanding of medicine and extensive global experience in drug and business development.
  • Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies.

OncoArendi Therapeutics supervisory board welcomes international biopharmaceutical experts: Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński as its new members

Retrieved on: 
Friday, January 14, 2022 - 7:00am

WARSAW, Poland, Jan. 14, 2022 /PRNewswire/ -- OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to discover and develop first in class small molecule drug candidates that directly modulate RNA and unexplored protein targets to treat multiple incurable diseases, announces the appointment of Nancy Van Osselaer, Paul van der Horst and Rafal Kamiński to its Supervisory Board. These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.

Key Points: 
  • These appointments bring considerable international experience to the Company across all stages of drug development as well as in finance and business development.
  • Marcin Szumowski, Co-founder & CEO, commented, "We arepleased towelcome Nancy, Paul and Rafal as new members to the Supervisory Board.
  • Together, they bring a deep understanding of medicine and extensive global experience in drug and business development.
  • Dr Van Osselaer is an experienced global biopharmaceutical professional with over 25 years experience leading drug development projects at leading pharmaceutical companies.

DGAP-News: Aareon CEO Dr Manfred Alflen has announced his retirement from the operating business in March 2022 - Hartmut Thomsen to take over as Chairman of the Management Board

Retrieved on: 
Thursday, January 13, 2022 - 10:03am

Wiesbaden/Mainz, 13 January 2022 - Dr Manfred Alflen (61), Chairman of the Management Board of Aareon AG, has announced that he will retire from the operating business with effect from 31 March 2022.

Key Points: 
  • Wiesbaden/Mainz, 13 January 2022 - Dr Manfred Alflen (61), Chairman of the Management Board of Aareon AG, has announced that he will retire from the operating business with effect from 31 March 2022.
  • Aareon AG's Supervisory Board has appointed Hartmut Thomsen (50) as Dr Alflen's successor, effective 1 April 2022.
  • I will remain close to Aareon, but no longer wish to be engaged in its operating business.
  • On behalf of the entire Supervisory Board, I would like to express our heartfelt thanks to Dr Alflen and his team.

DGAP-News: Encavis Asset Management AG acquires solar park in Spain with a total capacity of 56.3 megawatts for EIF II special fund

Retrieved on: 
Wednesday, January 12, 2022 - 7:01am

Encavis Asset Management AG (Encavis AM), subsidiary of SDAX-listed wind and solar park operator Encavis AG (Prime Standard, ISIN: DE0006095003, ticker symbol: ECV) makes first investment in Spain with acquisition of the solar park Archidona in the province of Mlaga (Andalusia).

Key Points: 
  • Encavis Asset Management AG (Encavis AM), subsidiary of SDAX-listed wind and solar park operator Encavis AG (Prime Standard, ISIN: DE0006095003, ticker symbol: ECV) makes first investment in Spain with acquisition of the solar park Archidona in the province of Mlaga (Andalusia).
  • For the first time in Encavis' asset management, the sale of energy generated by the facility has been secured through a long-term power purchase agreement (PPA).
  • The acquisition will be incorporated into the Encavis Infrastructure Fund II (EIF II) special fund, which is marketed exclusively by Bayern LB.
  • About Encavis Asset Management AG:
    Encavis Asset Management AG offers institutional investors tailor-made portfolios and fund solutions for investments in the growth market of renewable energies.

New addition to Management YK Group welcomes Michael von Stern as CFO

Retrieved on: 
Tuesday, January 11, 2022 - 2:05pm

With immediate effect, YK Group will have additional impetus in reaching its ambitious goals in the form of Michael von Stern, who joins Daniel Neuhaus (CEO), Tobias Conrad (CCO), and Nils Grabbert (CTO) on the Management Board als CFO.

Key Points: 
  • With immediate effect, YK Group will have additional impetus in reaching its ambitious goals in the form of Michael von Stern, who joins Daniel Neuhaus (CEO), Tobias Conrad (CCO), and Nils Grabbert (CTO) on the Management Board als CFO.
  • "We are absolutely delighted that, in Michael von Stern, we have found exactly the person we were looking for to fill this important position," says Daniel Neuhaus, CEO of YK Group.
  • In his new role at YK Group, Michael von Stern will be running financial operations; his remit will also encompass the legal and human resources briefs.
  • Daniel Neuhaus (CEO), Tobias Conrad (CCO), Nils Grabbert (CTO), and Michael von Stern (CFO) manage YK Group.

DGAP-News: PANTAFLIX AG: PANTALEON Films expands Management Board with Yoko Higuchi-Zitzmann

Retrieved on: 
Tuesday, January 11, 2022 - 8:03am

PANTALEON Films, a wholly owned film production subsidiary of PANTAFLIX AG (GSIN: A12UPJ , ISIN: DE000A12UPJ7 ), is expanding its Management Board.

Key Points: 
  • PANTALEON Films, a wholly owned film production subsidiary of PANTAFLIX AG (GSIN: A12UPJ , ISIN: DE000A12UPJ7 ), is expanding its Management Board.
  • Stephanie Schettler-Khler, COO of PANTAFLIX Management Board: "The entertainment industry is undergoing unprecedented upheaval.
  • We are very excited that Yoko will join Dan and Patrick in continuing the success story of our PANTALEON Films."
  • Yoko Higuchi-Zitzmann: "I sincerely thank PANTAFLIX Board members Nicolas Paalzow and Stephanie Schettler-Khler for the trust they have placed in me.

EQS-News: IMMOFINANZ: S IMMO offer price too low

Retrieved on: 
Monday, January 10, 2022 - 8:02am

The Executive Board and Supervisory Board therefore recommend that shareholders not accept the partial offer by S IMMO for approximately 10% of the outstanding IMMOFINANZ shares.

Key Points: 
  • The Executive Board and Supervisory Board therefore recommend that shareholders not accept the partial offer by S IMMO for approximately 10% of the outstanding IMMOFINANZ shares.
  • For example: The offer price is substantially lower than the current EPRA NTA per share of EUR 30.77 and represents a discount of roughly 25%.
  • Moreover, the S IMMO offer price does not reflect IMMOFINANZ's outstanding performance in 2021 or the potential of its value-creating strategy.
  • Consequently, we recommend that our shareholders not accept the offer from S IMMO because the specified price does not reflect the value of the company.

EQS-News: AT&S Austria Technologie & Systemtechnik AG: First half of 21/22 - Adjustment of classification of € 24.6 million hybrid capital

Retrieved on: 
Friday, January 7, 2022 - 6:02am

AT&S Austria Technologie & Systemtechnik AG: First half of 21/22 - Adjustment of classification of 24.6 million hybrid capital

Key Points: 
  • AT&S Austria Technologie & Systemtechnik AG: First half of 21/22 - Adjustment of classification of 24.6 million hybrid capital
    The issuer is solely responsible for the content of this announcement.
  • Leoben - AT&S republishes half-year report after pre-clearance procedure.
  • AT&S has a global presence with production sites in Austria (Leoben, Fehring) and plants in India (Nanjangud), China (Shanghai, Chongqing) and Korea (Ansan near Seoul).
  • For further information please visit www.ats.net
    Tel: +43 3842 200 2274; Mobile +43 664 7800 2274; p.gebhardt@ats.net